|1.03 0.02 (1.98%)||11-28 14:41|
|Targets||6-month :||1.38||1-year :||1.62|
|Resists||First :||1.19||Second :||1.38|
|Supports||First :||0.85||Second :||0.64|
|MAs||MA(5) :||0.99||MA(20) :||0.95|
|MA(100) :||0.95||MA(250) :||1.1|
|MACD||MACD :||0||Signal :||0|
|%K %D||K(14,3) :||58.9||D(3) :||57.4|
|52-week||High :||1.85||Low :||0.64|
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ CLSD ] has closed below upper band by 37.5%. Bollinger Bands are 3.7% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
|If tomorrow:||Open lower||Open higher|
|High:||1.06 - 1.07||1.07 - 1.07|
|Low:||0.99 - 0.99||0.99 - 1|
|Close:||1 - 1.01||1.01 - 1.02|
Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The company offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase 1/2a clinical trial; and CLS-301, an integrin inhibitor suspension for the treatment of diabetic macular edema and macular degeneration. The company has a collaboration with Bausch Health, Arctic Vision, REGENXBIO, Inc., and Aura Biosciences. Clearside Biomedical, Inc. was incorporated in 2011 and is headquartered in Alpharetta, Georgia.
Thu, 26 Oct 2023
3 Cheap Stocks to Buy Under $1 in October 2023 - InvestorPlace
|Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
|Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
|Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
|Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
|Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
|Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
|Shares Out||0 (M)|
|Shares Float||62 (M)|
|Held by Insiders||5.395e+007 (%)|
|Held by Institutions||7.1 (%)|
|Shares Short||351 (K)|
|Shares Short P.Month||0 (K)|
|EPS Est Next Qtrly||0|
|EPS Est This Year||0|
|EPS Est Next Year||0|
|Book Value (p.s.)||0|
|Profit Margin||0 %|
|Operating Margin||-821.2 %|
|Return on Assets (ttm)||-41.7 %|
|Return on Equity (ttm)||-1 %|
|Qtrly Rev. Growth||2.21e+006 %|
|Gross Profit (p.s.)||102.24|
|Sales Per Share||142.21|
|Qtrly Earnings Growth||-0.7 %|
|Operating Cash Flow||0 (M)|
|Levered Free Cash Flow||-24 (M)|
|Price to Book value||0|
|Price to Sales||0|
|Price to Cash Flow||-10.49|
|Dividend Pay Date||Invalid DateTime.|
|Ex-Dividend Date||Invalid DateTime.|